ES2531040T3 - Formas sólidas y procedimiento de preparación - Google Patents

Formas sólidas y procedimiento de preparación Download PDF

Info

Publication number
ES2531040T3
ES2531040T3 ES10775401T ES10775401T ES2531040T3 ES 2531040 T3 ES2531040 T3 ES 2531040T3 ES 10775401 T ES10775401 T ES 10775401T ES 10775401 T ES10775401 T ES 10775401T ES 2531040 T3 ES2531040 T3 ES 2531040T3
Authority
ES
Spain
Prior art keywords
solid forms
preparation procedure
formula
procedure
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10775401T
Other languages
English (en)
Inventor
Robin Clark
Doug Fry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corcept Therapeutics Inc
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43069047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2531040(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Application granted granted Critical
Publication of ES2531040T3 publication Critical patent/ES2531040T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Disintegrating Or Milling (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Forma sólida amorfa de un compuesto de Fórmula I:**Fórmula**
ES10775401T 2009-05-12 2010-05-11 Formas sólidas y procedimiento de preparación Active ES2531040T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17748309P 2009-05-12 2009-05-12
PCT/US2010/034382 WO2010132445A1 (en) 2009-05-12 2010-05-11 Solid forms and process for preparing

Publications (1)

Publication Number Publication Date
ES2531040T3 true ES2531040T3 (es) 2015-03-10

Family

ID=43069047

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10775401T Active ES2531040T3 (es) 2009-05-12 2010-05-11 Formas sólidas y procedimiento de preparación

Country Status (10)

Country Link
US (2) US8461172B2 (es)
EP (1) EP2429529B1 (es)
JP (1) JP5637568B2 (es)
CN (1) CN102421437B (es)
AU (1) AU2010247766B2 (es)
CA (1) CA2761255C (es)
DK (1) DK2429529T3 (es)
ES (1) ES2531040T3 (es)
IL (1) IL216305A0 (es)
WO (1) WO2010132445A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2313317T3 (es) * 2004-03-09 2009-03-01 Corcept Therapeutics, Inc. Moduladores del receptor de glucocorticoides de azadecalina de anillo condensado.
CA2821524A1 (en) 2011-01-07 2012-07-12 Corcept Therapeutics, Inc. Combination steroid and glucocorticoid receptor antagonist therapy
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US12226412B2 (en) 2012-05-25 2025-02-18 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
MX368167B (es) 2013-11-25 2019-09-23 Corcept Therapeutics Inc Moduladores de receptores de glucocorticoides de azadecalina octahidro fusionada.
CN107530339B (zh) 2015-03-30 2021-03-16 科赛普特治疗学股份有限公司 糖皮质激素受体拮抗剂联合糖皮质激素用于治疗肾上腺功能不全
MX383318B (es) 2015-08-13 2025-03-13 Corcept Therapeutics Inc Metodo para diagnosticar de manera diferencial el sindrome de cushing dependiente de la corticotropina.
KR102197526B1 (ko) 2016-01-19 2020-12-31 코어셉트 쎄라퓨틱스 인코포레이티드 이소성 쿠싱 증후군의 감별 진단
JP6847120B2 (ja) 2016-03-01 2021-03-24 コーセプト セラピューティクス， インコーポレイテッド チェックポイントインヒビターを強化するためのグルココルチコイドレセプターモジュレーターの使用
US9943505B2 (en) 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer
MX2019010732A (es) 2017-03-09 2019-11-01 Corcept Therapeutics Inc Uso de moduladores de receptor de glucocorticoide en el tratamiento de tumores secretores de catecolamina.
US10413540B2 (en) 2017-03-31 2019-09-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
MX393313B (es) 2017-06-20 2025-03-24 Corcept Therapeutics Inc Metodos de tratamiento de tumores neuroepiteliales usando moduladores selectivos del receptor de glucocorticoide.
IL263184A (en) 2018-11-21 2020-05-31 Yarden Yosef Method of treating cancer and compositions for same
WO2020132046A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
CN117281790A (zh) 2018-12-19 2023-12-26 科塞普特治疗公司 含有瑞拉可兰、杂芳基-酮稠合的氮杂十氢化萘化合物的药物制剂
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
EP3927345A4 (en) 2019-02-22 2022-12-21 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
US12440487B2 (en) 2019-10-16 2025-10-14 Corcept Therapeutics Incorporated Method of normalizing the neutrophil to lymphocyte ratio in cancer patients with a selective glucocorticoid receptor antagonist
WO2021119432A1 (en) 2019-12-11 2021-06-17 Corcept Therapeutics Incorporated Methods of treating antipsychotic-induced weight gain with miricorilant
CA3162636A1 (en) 2019-12-21 2021-06-24 Andreas G. MORAITIS Treatment of, and differential diagnosis between, acth-dependent cushing's syndrome and acth-independent cushing's syndrome
KR20220133275A (ko) 2020-01-29 2022-10-04 코어셉트 쎄라퓨틱스 인코포레이티드 선택적 글루코코르티코이드 수용체 조절제 (sgrm) 및 항체 체크포인트 억제제를 사용한 부신피질 암종의 치료
WO2022134033A1 (en) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
KR20250073629A (ko) 2022-10-06 2025-05-27 코어셉트 쎄라퓨틱스 인코포레이티드 글루코코르티코이드 수용체 조절제의 제형
EP4608402A1 (en) 2022-10-28 2025-09-03 Corcept Therapeutics Incorporated Treatments for amyotrophic lateral sclerosis using dazucorilant

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482847B2 (en) * 2000-10-03 2002-11-19 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
WO2005023254A1 (en) * 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
ES2313317T3 (es) 2004-03-09 2009-03-01 Corcept Therapeutics, Inc. Moduladores del receptor de glucocorticoides de azadecalina de anillo condensado.
AR052918A1 (es) * 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo

Also Published As

Publication number Publication date
US20100292477A1 (en) 2010-11-18
AU2010247766A1 (en) 2011-11-24
EP2429529B1 (en) 2015-01-14
CN102421437B (zh) 2014-03-19
AU2010247766B2 (en) 2015-05-21
CN102421437A (zh) 2012-04-18
EP2429529A1 (en) 2012-03-21
US20130245266A1 (en) 2013-09-19
US8889867B2 (en) 2014-11-18
US8461172B2 (en) 2013-06-11
JP2012526826A (ja) 2012-11-01
EP2429529A4 (en) 2012-11-07
JP5637568B2 (ja) 2014-12-10
WO2010132445A1 (en) 2010-11-18
CA2761255C (en) 2017-05-09
CA2761255A1 (en) 2010-11-18
IL216305A0 (en) 2012-01-31
DK2429529T3 (en) 2015-03-09

Similar Documents

Publication Publication Date Title
ES2531040T3 (es) Formas sólidas y procedimiento de preparación
CR20120121A (es) Compuestos de benzoxazepina como inhibidores de la pi3k y métodos de uso
PL3812360T3 (pl) Związki monochlorotrifluoropropenu oraz kompozycje i sposoby ich zastosowania
DOP2012000114A (es) Inhibidor bromodominio de benzodiazepina
EP2485589A4 (en) HETEROARYL-BTK INHIBITORS
BR112012005237A2 (pt) utilização de composições ternárias
HUE040355T2 (hu) Benzilbenzol SGLT2-inhibitor kristályformája
IL225867B (en) Coelenterazine substrates
BR112012006686A2 (pt) composto amida substituído
EP2630614A4 (en) ADVANCED FUNCTIONALITY OF DEVICES WITH REMOTE ACCESS
DK2262793T3 (da) Krystallinske former af nilotinib-hci
EP2742051A4 (en) AMORPHIC FORM OF DOLUTEGRAVIR
HUE035861T2 (hu) Egy pleuromutilin kristályos formája
BR112012000890A2 (pt) formas de base livre cristalina de um composto bifenil
CR20120513A (es) HETEROARIL-CICLOHEXIL-TETRAAZABENZO [e] AZULENOS
PL2493466T3 (pl) Nowe przeciwguzowe zastosowanie kabazytakselu
AP3659A (en) A novel formulation of meloxicam
EP2561123A4 (en) ELECTROCHEMICAL SYNTHESIS OF AN ARYL-ALKYL-TENSID PRECURSOR
FI20095644A0 (fi) Ulokkeen muodostaminen
BR112012002268A2 (pt) fotoestabailização de retinóides com compostos de alcóxicrileno
CO6801700A2 (es) Uso demetilhidroxietilcvelulosacomo aditivo de cemento
DK2506840T3 (da) Anvendelser af hæmmere af hypoksi-fremkaldende faktorer
DK2453858T3 (da) Fremgangsmåde
PL2576499T3 (pl) Sposób otrzymywania mieszaniny środków chelatujących
DK2516435T3 (da) Inhibitorer af AKT-aktivitet